+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab

Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab

Critical Reviews in Oncology/Hematology 37(1): 13-25

Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are probably due to complement and antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis. Phase II trials have demonstrated a strong activity of rituximab alone in indolent B non-Hodgkin lymphoma, especially in patients with follicular lymphoma. The most utilized dose-schedule is 375 mg/m(2) weekly x 4. The association with chemotherapy or with interferon-alpha increases Rituximab efficacy. More recently, Rituximab have showed activity also in diffuse large cell lymphoma, mantle cell lymphoma and in other B-malignancies. Good results have also been obtained utilizing Rituximab for in vivo purging. However, we are still far from having found a definite position for Rituximab in the treatment of lymphoproliferative disorders. The aim of future studies should be to develop new strategies that will hopefully produce the most effective Rituximab-based regimens in order to find the Rituximab key position in the treatment of B-malignancies

(PDF emailed within 0-6 h: $19.90)

Accession: 035980339

Download citation: RISBibTeXText

PMID: 11164715

DOI: 10.1016/s1040-8428(00)00069-x

Related references

Application of monoclonal anti-CD20 antibody rituximab in the treatment of non-Hodgkin's lymphoma. Vojnosanitetski Pregled 65(3): 229-233, 2008

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. Journal of Clinical Oncology 18(17): 3135-3143, 2000

Non-cytostatic treatment of malignancies. Anti-CD20 monoclonal antibody (Rituximab, Mabthera) in the treatment of non-Hodgkin's lymphoma. Vnitrni Lekarstvi 47 Suppl 1: 57-62, 2001

Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 8(10): 544-549, 2002

Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan. Cancer Chemotherapy and Pharmacology 48(Supplement 1): S85-S90, 2001

Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 101(2): 420-424, 2003

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochemical Society Transactions 25(2): 705-708, 1997

Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 29(3): 473-480, 2002

Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab). Nihon Rinsho. Japanese Journal of Clinical Medicine 60(1): 95-99, 2002

Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. International Journal of Hematology 74(1): 70-75, 2001

Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Annals of Oncology 11 Suppl 1: 117-121, 2000

Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl. Pediatric Hematology and Oncology 20(4): 339-344, 2003